Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma

被引：1
|
作者：
Gondran, Camille [1 ]
Ysebaert, Loic [1 ]
机构：
[1] Inst Univ Canc Toulouse, Serv dh matol, F-31100 Toulouse, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 11期
关键词：
Follicular lymphoma; Mosunetuzumab; Bi-specific antibody CD20-CD3; Cytokine release syndrome;
D O I：
10.1016/j.bulcan.2022.07.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1105 / 1106
页数：2
相关论文
共 50 条
  • [41] Usefulness of the α1-Blocker Doxazosin as a Third-Line Antihypertensive Drug
    Yuko Ohta
    Takuya Tsuchihashi
    Uran Onaka
    Kimika Eto
    Michio Ueno
    Hypertension Research, 2007, 30 : 301 - 306
  • [42] Usefulness of the α1-blocker doxazosin as a third-line antihypertensive drug
    Ohta, Yuko
    Tsuchihashi, Takuya
    Onaka, Uran
    Eto, Kimika
    Ueno, Michio
    HYPERTENSION RESEARCH, 2007, 30 (04) : 301 - 306
  • [43] Risk Factors for Infection Following Third-line Therapy for Overactive Bladder
    Noblett K.L.
    Lane F.
    Current Bladder Dysfunction Reports, 2017, 12 (4) : 268 - 272
  • [44] Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
    Alsina, Maria
    Tabernero, Josep
    Diez, Marc
    CANCERS, 2022, 14 (06)
  • [45] INFLIXIMAB AS THIRD-LINE THERAPY FOR DIFFICULT-TO-TREAT AUTOIMMUNE HEPATITIS
    Weiler-Normann, Christina
    Wiegard, Christiane C.
    Glaubke, Claudia
    Quaas, Alexander
    Schramm, Christoph
    Lahse, Ansgar W.
    HEPATOLOGY, 2010, 52 (04) : 1118A - 1118A
  • [46] OVERACTIVE BLADDER IN MEN: MEDICATION ABANDONMENT AND LACK OF THIRD-LINE THERAPY
    Woff, Erika
    Cook, Thomas
    Gore, John
    Kirby, Anna
    Gill, Bradley
    JOURNAL OF UROLOGY, 2019, 201 (04): : E567 - E567
  • [47] Case Presentations: Allograft or Third-Line Therapy in Very Resistant CML
    Radich, Jerald P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S32 - S33
  • [48] Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response
    Salles, Gilles
    Tilly, Herve
    Chaidos, Aristeidis
    Mckay, Pam
    Phillips, Tycel J.
    Assouline, Sarit E.
    Batlevi, Connie Lee
    Campbell, Philip
    Ribrag, Vincent
    Damaj, Gandhi Laurent
    Dickinson, Michael
    Jurczak, Wojciech
    Kazmierczak, Maciej
    Opat, Stephen
    Radford, John A.
    Schmitt, Anna
    Whalen, Jennifer
    Hamlett, Anthony
    Kamp, Beth
    Adib, Deyaa
    Morschhauser, Franck
    BLOOD, 2020, 136
  • [49] Analyzing Efficacy Outcomes From the Phase 2 Study of Single-Agent Tazemetostat as Third-Line Therapy in Patients With Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 2 - 3
  • [50] Delays in third-line antiretroviral therapy and outcomes in North West province
    Majova, Babalwa
    Variava, Ebrahim
    Martinson, Neil
    SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 2022, 23 (01)
12345